Press Releases United Therapeutics Corporation

Equities

UTHR

US91307C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 10/12/2025 GMT			5-day change	1st Jan Change
484.86 ^USD	+1.78%		+0.81%	+37.42%

12-09	United Therapeutics Insider Sold Shares Worth $10,050,597, According to a Recent SEC Filing	MT
12-08	United Therapeutics Insider Sold Shares Worth $3,870,056, According to a Recent SEC Filing	MT

Press Releases

United Therapeutics Corporation to Present at Upcoming Investor Conferences	11-04	BU
First clinical trial of pig kidney transplants gets underway	11-03	AQ
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease	11-03	BU
United Therapeutics: Q3 Earnings Snapshot	10-29	AQ
United Therapeutics : Third Quarter 2025 Factsheet	10-29	PU
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results	10-29	BU
United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025	10-15	BU
United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting	10-13	BU
United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis	09-19	BU
United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum	09-16	BU
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress	09-12	BU
United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis	09-02	BU
United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference	08-29	BU
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program	08-01	BU
United Therapeutics: Q2 Earnings Snapshot	07-30	AQ
United Therapeutics : Second Quarter 2025 Factsheet	07-30	PU
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results	07-30	BU
United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025	07-16	BU
United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver	06-24	BU
United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension	06-23	BU
United Therapeutics: Q1 Earnings Snapshot	04-30	AQ
United Therapeutics Corporation Reports First Quarter 2025 Financial Results	04-30	BU
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference	04-21	BU
United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025	04-16	BU
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions	04-04	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

United Therapeutics delivers 18th consecutive quarter of topline growth

June 17, 2025 at 08:39 am